Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
VMF
0
EDQM
0
USP
0
JP
0
Others
0
Australia
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
Annual Reports
NA
Regulatory FDF Prices
NA
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers


1. 17-deacetylnorgestimate
2. 18,19-dinorpregn-4-en-20-yn-3-one, 13-ethyl-17-hydroxy-, Oxime, (17alpha)-
3. Levonorgestrel Oxime
4. Levonorgestrel Oxime, (3e,17alpha)-isomer
5. Levonorgestrel Oxime, (3z,17alpha)-isomer
6. Lngo
7. Progestin Norelgestromin
1. Levonorgestrel Oxime
2. Norplant 3-oxime
3. D-norgestrel 3-oxime
4. 18-methylnorethindrone Oxime
5. 17-deacetylnorgestimate
6. 53016-31-2
7. 17-deacylnorgestimate
8. (8r,9s,10r,13s,14s,17r)-13-ethyl-17-ethynyl-3-hydroxyimino-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-ol
9. Deacetylnorgestimate
10. Norgestimate Metabolite Norelgestromin
11. Norelgestromin (17-deacetylnorgestimate)
12. Brn 4202099
13. Unii-r0tay3x631
14. Norelgestromin [usan:inn:ban]
15. Rwj 10553
16. Levonorgestrel 3-oxime
17. 17-deacetyl Norgestimate
18. 18,19-dinorpregn-4-en-20-yn-3-one, 13-ethyl-17-hydroxy-, Oxime, (17alpha)-
19. R0tay3x631
20. Chembl4791392
21. Dtxsid9046788
22. 13-ethyl-17-hydroxy-18,19-dinor-17alpha-pregn-4-en-20-yn-3-one Oxime
23. Db06713
24. 18,19-dinorpregn-4-en-20-yn-3-one, 13-ethyl-17-hydroxy-, Oxime, (8-alpha,9-beta,10-alpha,13-alpha,14-beta)-
25. 17-deacylnorgestimate17-deacetyl Norgestimate
| Molecular Weight | 327.5 g/mol |
|---|---|
| Molecular Formula | C21H29NO2 |
| XLogP3 | 3.6 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 3 |
| Rotatable Bond Count | 2 |
| Exact Mass | 327.219829168 g/mol |
| Monoisotopic Mass | 327.219829168 g/mol |
| Topological Polar Surface Area | 52.8 Ų |
| Heavy Atom Count | 24 |
| Formal Charge | 0 |
| Complexity | 642 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 6 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 1 |
| Covalently Bonded Unit Count | 1 |
Norelgestromin is used for contraception and menopausal hormonal therapy. Norelgestromin may potentially be used in breast cancer treatment due to its inhibitory effect on estrone sulfatase . They convert sulfated steroid precursors to estrogen during pregnancy.
Norelgestromin is used for contraception and menopausal hormonal therapy transdermally or in combination with ethinyl estradiol as a vaginal ring. Norelgestromin, in combination with ethinyl estradiol inhibits ovulation by suppressing gonadotropins.
Contraceptive Agents, Hormonal
Contraceptive agents that act on the ENDOCRINE SYSTEM. (See all compounds classified as Contraceptive Agents, Hormonal.)
G03AA13
S76 | LUXPHARMA | Pharmaceuticals Marketed in Luxembourg | Pharmaceuticals marketed in Luxembourg, as published by d'Gesondheetskeess (CNS, la caisse nationale de sante, www.cns.lu), mapped by name to structures using CompTox by R. Singh et al. (in prep.). List downloaded from https://cns.public.lu/en/legislations/textes-coordonnes/liste-med-comm.html. Dataset DOI:10.5281/zenodo.4587355
Norelgestromin inhibits estrone sulfatase, which converts sulfated steroid precursors to estrogen during pregnancy. Norgelgestromin/ethinylestradiol suppresses follicular development, induces changes to the endometrium, which decreases chances of implantation and thickens the cervical mucus, impeding sperm swimming into the uterus. It also has similar agonisting binding affinities as its parent compound, Norgestimate, for progesterone and estrogen receptors.

API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us
Related Excipient Companies
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
ANALYTICAL
ABOUT THIS PAGE
54
PharmaCompass offers a list of Norelgestromin API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Norelgestromin manufacturer or Norelgestromin supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Norelgestromin manufacturer or Norelgestromin supplier.
PharmaCompass also assists you with knowing the Norelgestromin API Price utilized in the formulation of products. Norelgestromin API Price is not always fixed or binding as the Norelgestromin Price is obtained through a variety of data sources. The Norelgestromin Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Levonorgestrel Oxime manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Levonorgestrel Oxime, including repackagers and relabelers. The FDA regulates Levonorgestrel Oxime manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Levonorgestrel Oxime API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Levonorgestrel Oxime manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Levonorgestrel Oxime supplier is an individual or a company that provides Levonorgestrel Oxime active pharmaceutical ingredient (API) or Levonorgestrel Oxime finished formulations upon request. The Levonorgestrel Oxime suppliers may include Levonorgestrel Oxime API manufacturers, exporters, distributors and traders.
click here to find a list of Levonorgestrel Oxime suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Levonorgestrel Oxime DMF (Drug Master File) is a document detailing the whole manufacturing process of Levonorgestrel Oxime active pharmaceutical ingredient (API) in detail. Different forms of Levonorgestrel Oxime DMFs exist exist since differing nations have different regulations, such as Levonorgestrel Oxime USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Levonorgestrel Oxime DMF submitted to regulatory agencies in the US is known as a USDMF. Levonorgestrel Oxime USDMF includes data on Levonorgestrel Oxime's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Levonorgestrel Oxime USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Levonorgestrel Oxime suppliers with USDMF on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Levonorgestrel Oxime as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Levonorgestrel Oxime API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Levonorgestrel Oxime as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Levonorgestrel Oxime and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Levonorgestrel Oxime NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Levonorgestrel Oxime suppliers with NDC on PharmaCompass.
Levonorgestrel Oxime Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Levonorgestrel Oxime GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Levonorgestrel Oxime GMP manufacturer or Levonorgestrel Oxime GMP API supplier for your needs.
A Levonorgestrel Oxime CoA (Certificate of Analysis) is a formal document that attests to Levonorgestrel Oxime's compliance with Levonorgestrel Oxime specifications and serves as a tool for batch-level quality control.
Levonorgestrel Oxime CoA mostly includes findings from lab analyses of a specific batch. For each Levonorgestrel Oxime CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Levonorgestrel Oxime may be tested according to a variety of international standards, such as European Pharmacopoeia (Levonorgestrel Oxime EP), Levonorgestrel Oxime JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Levonorgestrel Oxime USP).